| 000 | 01836 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514052504.0 | ||
| 264 | 0 | _c20030326 | |
| 008 | 200303s 0 0 eng d | ||
| 022 | _a0278-5846 | ||
| 024 | 7 |
_a10.1016/s0278-5846(02)00222-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRodríguez-Pérez, Víctor | |
| 245 | 0 | 0 |
_aOlanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. _h[electronic resource] |
| 260 |
_bProgress in neuro-psychopharmacology & biological psychiatry _cOct 2002 |
||
| 300 |
_a1055-62 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 | _aBenzodiazepines |
| 650 | 0 | 4 |
_aBody Weight _xdrug effects |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOlanzapine |
| 650 | 0 | 4 |
_aPirenzepine _xadverse effects |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 |
_aSchizophrenia _xdrug therapy |
| 700 | 1 | _aLópez, Aurea | |
| 700 | 1 | _aBlanco, Clara | |
| 700 | 1 | _aPeña, Carmen | |
| 700 | 1 | _aLópez, Ana | |
| 700 | 1 | _aAbel, Ana | |
| 700 | 1 | _aGómez, Yolanda | |
| 700 | 1 | _aFerreiro, Maria José | |
| 700 | 1 | _aRego, Carmen | |
| 700 | 1 | _aLópez, Ana | |
| 700 | 1 | _aCudeiro, Fernando | |
| 700 | 1 | _aAlvarez, Vicente | |
| 700 | 1 | _aPrieto, Ramón | |
| 700 | 1 | _aCiudad, Antonio | |
| 773 | 0 |
_tProgress in neuro-psychopharmacology & biological psychiatry _gvol. 26 _gno. 6 _gp. 1055-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0278-5846(02)00222-1 _zAvailable from publisher's website |
| 999 |
_c12258750 _d12258750 |
||